We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 51 for:    Recruiting, Not yet recruiting, Available Studies | "Duodenal Diseases"
Previous Study | Return to List | Next Study

Endoscopic Characteristics of Duodenal and Ampullary Lesions (DUO/AMP-LST)

This study is currently recruiting participants.
Verified November 2017 by Professor Michael Bourke, Western Sydney Local Health District
Sponsor:
ClinicalTrials.gov Identifier:
NCT01556399
First Posted: March 16, 2012
Last Update Posted: November 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Professor Michael Bourke, Western Sydney Local Health District
  Purpose
The purpose is to investigate whether polyps that look different at endoscopy, have formed via different mutations and have different risks of turning into cancer.

Condition Intervention
Duodenal Diseases Other: Tissue Sampling

Study Type: Observational
Study Design: Observational Model: Case-Control
Time Perspective: Prospective
Official Title: A Correlation of the Endoscopic Characteristics of Duodenal and Ampullary Laterally Spreading Tumours With Their Somatic or Germline Mutations.

Resource links provided by NLM:


Further study details as provided by Professor Michael Bourke, Western Sydney Local Health District:

Primary Outcome Measures:
  • Significant differences in molecular abnormalities. [ Time Frame: Specimens will be stored and used for up to 15 years ]
    The aim of this project is to look for statistically significant differences in molecular abnormalities from the three known genetic pathways, between the two different morphological types, granular and non-granular, to potentially demonstrate that these different polyps form via different genetic pathways.


Biospecimen Retention:   Samples With DNA
Adenoma tissue sample and control "regular" tissue sample

Estimated Enrollment: 350
Study Start Date: November 2011
Estimated Study Completion Date: November 2021
Estimated Primary Completion Date: November 2020 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Duodenal adenomas
Patients who consent to participate in this study will have a small sample of their adenoma and normal tissue sent for molecular testing.
Other: Tissue Sampling
A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.

Detailed Description:

Laterally spreading tumours (LSTs), are polyps that have a lateral extension along the duodenal wall with minimal vertical growth. It has become evident over the last few years that rather than being a single entity requiring an accumulation of mutations, Duodenal and ampullary cancer is in fact a heterogenous disease forming via multiple distinct genetic pathways. It is therefore hypothesised that different polyp types have different genetic abnormalities, and potentially form via distinct genetic pathways, although this theory has not been widely examined.

This knowledge would be important in furthering our understanding of the development of cancer. There is accumulating evidence that genetic abnormalities may be a better predictor of cancer behaviour than histological grade. Additionally, guidelines for endoscopy surveillance are currently a one size fits all approach that do not reflect the genetic heterogeneity of the disease and the knowledge that only 5% of polyps progress to cancer. Genetic studies may assess future cancer risk to a person in polyps once removed and plan surveillance endoscopy frequency.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with Duodenal and/or ampullary adenomas or cancers.
Criteria

Inclusion Criteria:

  • Intention to perform Endoscopic Mucosal Resection
  • Adenoma equal to or greater than 20mm
  • over 18 years of age
  • Able to give informed consent to involvement in trial

Exclusion Criteria:

  • Pregnancy
  • Lactation: currently breastfeeding
  • Taken clopidogrel within 7 days
  • Taken warfarin within 5 days
  • Had full therapeutic dose unfractionated heparin within 6 hours
  • Had full therapeutic dose low molecular weight heparin (LMWH) within 12 hours
  • Known clotting disorder
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01556399


Contacts
Contact: Michael Bourke, MBBS, FRACP 0409042019 bec2153@gmail.com
Contact: Rebecca Sonson, BM 98459779 bec2153@gmail.com

Locations
Australia, New South Wales
Westmead Hospital Recruiting
Westmead, New South Wales, Australia, 2145
Contact: Michael Bourke, MBBS, FRACP    0409042019    bec2153@gmail.com   
Contact: Rebecca Sonson, BN    98459779    bec2153@gmail.com   
Sponsors and Collaborators
Professor Michael Bourke
Investigators
Principal Investigator: Michael Bourke, MBBS, FRACP Western Sydney Local Health District
  More Information

Responsible Party: Professor Michael Bourke, Director of Gastrointestinal Endoscopy, Western Sydney Local Health District
ClinicalTrials.gov Identifier: NCT01556399     History of Changes
Other Study ID Numbers: LST-UGIM
First Submitted: March 15, 2012
First Posted: March 16, 2012
Last Update Posted: November 16, 2017
Last Verified: November 2017

Keywords provided by Professor Michael Bourke, Western Sydney Local Health District:
Duodenal adenoma
Ampullary adenoma

Additional relevant MeSH terms:
Duodenal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases